- Home
- CURI vs ADVM Comparison
CURI vs ADVM Comparison
Compare CURI & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURI
- ADVM
- Stock Information
- Founded
- CURI 2015
- ADVM 2006
- Country
- CURI United States
- ADVM United States
- Employees
- CURI N/A
- ADVM N/A
- Industry
- CURI Movies/Entertainment
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CURI Consumer Discretionary
- ADVM Health Care
- Exchange
- CURI Nasdaq
- ADVM Nasdaq
- Market Cap
- CURI 101.0M
- ADVM 119.6M
- IPO Year
- CURI N/A
- ADVM 2014
- Fundamental
- Price
- CURI $2.09
- ADVM $4.40
- Analyst Decision
- CURI Strong Buy
- ADVM Strong Buy
- Analyst Count
- CURI 1
- ADVM 6
- Target Price
- CURI $3.00
- ADVM $27.83
- AVG Volume (30 Days)
- CURI 276.3K
- ADVM 198.6K
- Earning Date
- CURI 03-19-2025
- ADVM 11-04-2024
- Dividend Yield
- CURI 4.83%
- ADVM N/A
- EPS Growth
- CURI N/A
- ADVM N/A
- EPS
- CURI N/A
- ADVM N/A
- Revenue
- CURI $51,775,000.00
- ADVM $1,000,000.00
- Revenue This Year
- CURI N/A
- ADVM N/A
- Revenue Next Year
- CURI $9.18
- ADVM $1,342.84
- P/E Ratio
- CURI N/A
- ADVM N/A
- Revenue Growth
- CURI N/A
- ADVM N/A
- 52 Week Low
- CURI $0.45
- ADVM $4.01
- 52 Week High
- CURI $3.00
- ADVM $29.70
- Technical
- Relative Strength Index (RSI)
- CURI 68.14
- ADVM 38.38
- Support Level
- CURI $1.53
- ADVM $4.20
- Resistance Level
- CURI $2.17
- ADVM $4.78
- Average True Range (ATR)
- CURI 0.15
- ADVM 0.31
- MACD
- CURI 0.07
- ADVM 0.04
- Stochastic Oscillator
- CURI 88.41
- ADVM 35.45
About CURI CuriosityStream Inc.
CuriosityStream Inc is a media and entertainment company. It offers premium video programming across the principal categories of factual entertainment, including science, history, society, nature, lifestyle, and technology. Its mission is to provide premium real entertainment that informs, enchants, and inspires. Its product and services are Direct to Consumer Business, Partner Direct Business, Bundled Distribution, Content Licensing, Enterprise Subscriptions, and Others. The majority of the revenue comes from the Direct to direct-to-consumer business.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.